PriceTargets.com logo

NASDAQ:AMED - Amedisys Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $234.67
  • Forecasted Upside: 40.51 %
  • Number of Analysts: 15
  • Breakdown:
  • 1 Sell Ratings
  • 5 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$167.01 As of 10/25/2021 01:00 AM ET
▼ -2.37 (-1.40%)

This chart shows the closing price for AMED by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Amedisys Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AMED and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMED

Analyst Price Target is $234.67
▲ +40.51% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for Amedisys in the last 3 months. The average price target is $234.67, with a high forecast of $350.00 and a low forecast of $150.00. The average price target represents a 40.51% upside from the last price of $167.01.

This chart shows the closing price for AMED for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 15 investment analysts is to buy stock in Amedisys. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
5/4/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
8/2/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
10/31/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
1/29/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
4/29/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/28/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
9/26/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
10/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/13/2021TruistLower Price TargetBuy$255.00 ➝ $190.00Medium
10/13/2021Truist SecuritiesLower Price TargetBuy$255.00 ➝ $190.00Medium
9/30/2021BMO Capital MarketsLower Price TargetNeutral ➝ Market Perform$240.00 ➝ $180.00Low
9/27/2021SVB LeerinkInitiated CoverageMarket Perform$170.00Low
9/23/2021UBS GroupInitiated CoverageSell$150.00High
9/17/2021OppenheimerReiterated RatingBuy$265.00Medium
9/9/2021CowenInitiated CoverageMarket Perform$195.00Medium
8/11/2021Credit Suisse GroupLower Price TargetOutperform$330.00 ➝ $250.00Medium
8/10/2021BenchmarkLower Price TargetBuy$325.00 ➝ $235.00Medium
8/9/2021Raymond JamesLower Price TargetOutperform$325.00 ➝ $250.00High
8/6/2021StephensLower Price TargetReduce ➝ Equal Weight$310.00 ➝ $237.00High
8/6/2021OppenheimerLower Price TargetOutperform$325.00 ➝ $265.00High
8/5/2021Bank of AmericaDowngradeBuy ➝ Neutral$220.00High
4/30/2021Royal Bank of CanadaBoost Price TargetOutperform$335.00 ➝ $350.00High
2/23/2021BenchmarkBoost Price TargetPositive ➝ Buy$275.00 ➝ $325.00Medium
2/8/2021Deutsche Bank AktiengesellschaftBoost Price TargetBuy$275.00 ➝ $340.00Medium
1/5/2021TruistBoost Price Target$280.00 ➝ $325.00N/A
11/3/2020BarclaysBoost Price TargetOverweight$290.00 ➝ $298.00Medium
10/30/2020Deutsche Bank AktiengesellschaftBoost Price TargetBuy$260.00 ➝ $275.00High
10/30/2020Credit Suisse GroupBoost Price TargetOutperform$246.00 ➝ $280.00High
9/21/2020OppenheimerBoost Price TargetOutperform$250.00 ➝ $260.00High
9/10/2020StephensReiterated RatingEqual Weight$235.00 ➝ $245.00Medium
9/2/2020BMO Capital MarketsBoost Price TargetMarket Perform$250.00 ➝ $270.00High
8/20/2020BarclaysInitiated CoverageOverweight$290.00 ➝ $290.00High
7/30/2020SunTrust BanksBoost Price TargetBuy$260.00 ➝ $270.00Medium
7/30/2020BenchmarkBoost Price TargetBuy$210.00 ➝ $250.00Medium
7/30/2020Royal Bank of CanadaBoost Price TargetOutperform$218.00 ➝ $260.00Medium
7/30/2020Deutsche Bank AktiengesellschaftBoost Price TargetBuy$220.00 ➝ $260.00Medium
7/30/2020Raymond JamesBoost Price TargetOutperform$210.00 ➝ $255.00Medium
7/29/2020Jefferies Financial GroupBoost Price TargetBuy$225.00 ➝ $250.00Medium
7/10/2020SunTrust BanksBoost Price TargetBuy$240.00 ➝ $260.00Medium
6/18/2020BenchmarkUpgradeHold ➝ Buy$210.00High
5/21/2020SunTrust BanksBoost Price TargetBuy$225.00 ➝ $240.00High
5/11/2020UBS GroupLower Price TargetNeutral$208.00 ➝ $190.00Low
5/11/2020Raymond JamesLower Price TargetOutperform$225.00 ➝ $210.00Medium
5/10/2020Royal Bank of CanadaReiterated RatingBuy$218.00Medium
5/7/2020BenchmarkDowngradeBuy ➝ HoldHigh
4/27/2020OppenheimerReiterated RatingBuy$215.00Medium
3/9/2020BenchmarkUpgradeHold ➝ Buy$205.00High
2/21/2020StephensBoost Price TargetEqual Weight$180.00 ➝ $200.00Low
2/21/2020UBS GroupBoost Price TargetNeutral$154.00 ➝ $208.00Low
2/21/2020BMO Capital MarketsReiterated RatingMarket Perform$215.00Low
2/21/2020Credit Suisse GroupBoost Price TargetOutperform$206.00 ➝ $214.00Low
2/20/2020SunTrust BanksBoost Price TargetBuy$185.00 ➝ $225.00Low
2/20/2020Raymond JamesBoost Price TargetOutperform$200.00 ➝ $225.00Low
1/17/2020Credit Suisse GroupInitiated CoverageOutperform$206.00Low
1/3/2020Raymond JamesSet Price TargetOutperform$144.00 ➝ $200.00Medium
12/18/2019SunTrust BanksBoost Price TargetBuy$175.00 ➝ $185.00Low
12/6/2019BMO Capital MarketsInitiated CoverageMarket Perform$170.00Medium
11/26/2019Bank of AmericaBoost Price TargetBuy$170.00 ➝ $178.00Low
11/1/2019Robert W. BairdUpgradeNeutral ➝ Outperform$140.00 ➝ $160.00High
10/22/2019StephensReiterated RatingEqual Weight$145.00Low
10/21/2019StephensInitiated CoverageEqual Weight$145.00Low
9/16/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuy$155.00Low
8/5/2019BarclaysBoost Price TargetEqual Weight$120.00 ➝ $125.00High
8/2/2019Royal Bank of CanadaBoost Price TargetOutperform$150.00Low
8/1/2019OppenheimerBoost Price Target$140.00 ➝ $150.00Low
7/15/2019Raymond JamesBoost Price TargetOutperform$140.00 ➝ $144.00Medium
7/8/2019Jefferies Financial GroupSet Price TargetBuy$150.00Low
5/2/2019Raymond JamesUpgradeMarket Perform ➝ Outperform$140.00High
3/21/2019BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$115.00 ➝ $120.00Low
3/1/2019Craig HallumLower Price TargetHold$132.00 ➝ $124.00Low
3/1/2019SunTrust BanksBoost Price TargetBuy$145.00Low
2/5/2019BenchmarkDowngradeBuy ➝ Hold$136.64High
12/14/2018BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$130.00High
11/16/2018UBS GroupInitiated CoverageNeutral ➝ Neutral$126.00Medium
10/30/2018BenchmarkUpgradeHold ➝ Buy$125.00High
10/26/2018Craig HallumDowngradeBuy ➝ Hold$116.00 ➝ $104.00Medium
10/11/2018Robert W. BairdBoost Price TargetNeutral$105.00 ➝ $120.00High
10/11/2018SunTrust BanksBoost Price TargetBuy$130.00High
10/11/2018Cantor FitzgeraldBoost Price TargetNeutral$117.00 ➝ $125.00High
9/18/2018Bank of AmericaSet Price TargetBuy$139.00Low
9/13/2018Cantor FitzgeraldInitiated CoverageNeutral$117.00Low
9/13/2018Canaccord GenuityInitiated CoverageNeutral$117.00Low
8/3/2018Royal Bank of CanadaBoost Price TargetOutperform$115.00Medium
7/3/2018Bank of AmericaUpgradeNeutral ➝ Buy$88.00 ➝ $97.00Medium
6/5/2018Bank of AmericaBoost Price TargetNeutral ➝ Neutral$73.00 ➝ $78.00Medium
6/5/2018StephensReiterated RatingHold$78.00High
6/5/2018Robert W. BairdBoost Price TargetNeutral ➝ Neutral$67.00 ➝ $72.00High
5/9/2018Craig HallumBoost Price TargetBuy$60.00 ➝ $82.00Low
5/8/2018Robert W. BairdBoost Price TargetNeutral ➝ Neutral$66.00High
3/19/2018Royal Bank of CanadaUpgradeSector Perform ➝ OutperformLow
3/1/2018Robert W. BairdSet Price TargetNeutral ➝ Hold$60.00 ➝ $66.00Medium
3/1/2018OppenheimerBoost Price TargetOutperform$68.00 ➝ $63.00High
2/28/2018Jefferies Financial GroupSet Price TargetBuy$70.00Medium
11/21/2017William BlairReiterated RatingOutperformN/A
11/10/2017SunTrust BanksReiterated RatingBuy$70.00N/A
11/10/2017Robert W. BairdBoost Price TargetNeutral$50.00 ➝ $60.00N/A
11/9/2017Craig HallumReiterated RatingBuy$55.00 ➝ $68.00N/A
11/9/2017Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$56.00 ➝ $62.00N/A
11/9/2017BenchmarkReiterated RatingBuy ➝ HoldN/A
11/8/2017MizuhoReiterated RatingBuy$55.00 ➝ $65.00N/A
11/2/2017BenchmarkUpgradeHold ➝ Buy$56.00N/A
11/2/2017MizuhoUpgradeNeutral ➝ Buy$55.00 ➝ $65.00N/A
10/23/2017Royal Bank of CanadaReiterated RatingHoldN/A
10/12/2017Jefferies Financial GroupReiterated RatingBuy$60.00N/A
10/9/2017SunTrust BanksReiterated RatingBuy$60.00N/A
10/4/2017Robert W. BairdReiterated RatingHold$50.00Low
9/15/2017OppenheimerReiterated RatingBuy$60.00Low
8/21/2017Bank of AmericaInitiated CoverageNeutral ➝ Neutral$55.00Low
7/26/2017MizuhoDowngradeBuy ➝ Neutral$50.00High
6/5/2017Royal Bank of CanadaReiterated RatingHold$56.00Low
5/4/2017StephensBoost Price TargetEqual Weight$50.00 ➝ $54.00Low
5/3/2017BenchmarkReiterated RatingHold ➝ Hold$50.00 ➝ $57.00High
5/3/2017MizuhoUpgradeNeutral ➝ Buy$65.00High
4/28/2017Jefferies Financial GroupReiterated RatingBuy$57.00Low
3/3/2017OppenheimerReiterated RatingOutperform$50.00 ➝ $59.00N/A
3/1/2017Jefferies Financial GroupBoost Price TargetBuy$50.00 ➝ $57.00N/A
3/1/2017MizuhoBoost Price TargetNeutral ➝ Neutral$33.00 ➝ $50.00N/A
1/27/2017BenchmarkInitiated CoverageHold$50.00N/A
1/17/2017Craig HallumSet Price TargetBuy$60.00N/A
1/13/2017Jefferies Financial GroupSet Price TargetBuy$50.00N/A
12/16/2016Craig HallumInitiated CoverageBuy$48.00N/A
11/9/2016MizuhoDowngradeBuy ➝ NeutralN/A
11/7/2016MizuhoUpgradeNeutral ➝ Buy$47.00N/A
11/4/2016MizuhoUpgradeNeutral ➝ Buy$47.00N/A
11/1/2016Jefferies Financial GroupReiterated RatingBuy$59.00 ➝ $50.00N/A
(Data available from 10/26/2016 forward)

News Sentiment Rating

0.28 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/30/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/29/2021
  • 0 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/28/2021
  • 7 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/28/2021
  • 4 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
8/27/2021
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/26/2021
  • 5 very positive mentions
  • 9 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
Mentions as of
10/26/2021

Current Sentiment

  • 5 very positive mentions
  • 9 positive mentions
  • 7 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Amedisys logo
Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The company was founded by William F. Borne in 1982 and is headquartered in Baton Rouge, LA.
Read More

Today's Range

Now: $167.01
Low: $164.29
High: $169.74

50 Day Range

MA: $168.16
Low: $137.95
High: $193.80

52 Week Range

Now: $167.01
Low: $137.82
High: $325.12

Volume

341,665 shs

Average Volume

266,086 shs

Market Capitalization

$5.45 billion

P/E Ratio

22.42

Dividend Yield

N/A

Beta

0.51

Frequently Asked Questions

What sell-side analysts currently cover shares of Amedisys?

The following Wall Street sell-side analysts have issued reports on Amedisys in the last year: Bank of America Co., Barclays PLC, Benchmark Co., BMO Capital Markets, Cowen Inc, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Oppenheimer Holdings Inc., Raymond James, Royal Bank of Canada, Stephens, SVB Leerink LLC, Truist, Truist Securities, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for AMED.

What is the current price target for Amedisys?

15 Wall Street analysts have set twelve-month price targets for Amedisys in the last year. Their average twelve-month price target is $234.67, suggesting a possible upside of 40.5%. Royal Bank of Canada has the highest price target set, predicting AMED will reach $350.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $150.00 for Amedisys in the next year.
View the latest price targets for AMED.

What is the current consensus analyst rating for Amedisys?

Amedisys currently has 1 sell rating, 5 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AMED will outperform the market and that investors should add to their positions of Amedisys.
View the latest ratings for AMED.

What other companies compete with Amedisys?

Other companies that are similar to Amedisys include Laboratory Co. of America, Quest Diagnostics, DaVita, Chemed, R1 RCM, AMN Healthcare Services, LHC Group, CorVel, MEDNAX, Tivity Health and Cross Country Healthcare.

How do I contact Amedisys' investor relations team?

Amedisys' physical mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider's listed phone number is (225) 292-2031 and its investor relations email address is [email protected] The official website for Amedisys is www.amedisys.com.